Prostatype Genomics AB (OSTO:PROGEN) Net Issuance of Preferred Stock : kr0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Prostatype Genomics AB's net issuance of preferred for the three months ended in Jun. 2023 was kr0.00 Mil. The number is 0, which means that Prostatype Genomics AB has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Prostatype Genomics AB's net issuance of preferred for the trailing twelve months (TTM) ended in Jun. 2023 was kr0.00 Mil.

Prostatype Genomics AB Net Issuance of Preferred Stock Historical Data

The historical data trend for Prostatype Genomics AB's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Net Issuance of Preferred Stock Chart

Prostatype Genomics AB Annual Data

Trend

Jun18

Jun19

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Prostatype Genomics AB Quarterly Data
	Jun18	Jun19	Mar20	Jun20	Sep20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial											-	-	-	-	-

Prostatype Genomics AB Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Prostatype Genomics AB Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB (OSTO:PROGEN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

PGO:Germany

Address

Gustaf III:s Boulevard 34, Solna, SWE, 169 73

Website

https://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines